{
"info": {
"nct_id": "NCT01229865",
"official_title": "",
"inclusion_criteria": "1. Histologically or cytologically confirmed advanced DTC (papillary, follicular, Hurthle cell);\n2. Absence of sensitivity to therapeutic radioiodine;\n3. Measurable disease, defined as at least one non-bony lesion that can be accurately measured in at least one dimension as confirmed with spiral CT scan\n4. Life expectancy >3 months; ECOG performance status (PS) 0, 1, or 2; Karnofsky performance status of ≥60%;\n5. Subjects with a normal/acceptable hematological profile\n6. Subjects with adequate renal function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Presence of any of the following:\n\n * Radiotherapy or chemotherapy <4 weeks prior to baseline visit; (Concurrent and/or prior therapy with octreotide will be allowed, provided tumor progression on this therapy has been demonstrated; Concurrent and/or prior therapy with biphosphonates will be allowed)\n * Radiotherapy to ≥25% of bone marrow;\n2. Major surgery <4 weeks prior to baseline visit;\n3. Any other ongoing investigational agents within 4 weeks before dosing;\n4. Subjects who suffered from an acute cardiac event within the last 12 months, including myocardial infarction, cardiac arrythmia, admission for unstable angina, cardiac angioplasty, or stenting;\n5. QTc prolongation (defined as QTc interval ≥500 msecs) or other significant ECG abnormalities (e.g. frequent ventricular ectopy, evidence of ongoing myocardial ischemia);\n6. Subjects with active vascular disease, either myocardial or peripheral;\n7. Subjects with proliferative and/or vascular retinopathy;\n8. Subjects with known active liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune) other than related to tumor metastases;\n9. Subjects with known CNS metastatic disease (Exception: Subjects with treated CNS metastases stable by radiographic examinations >6 months after definitive therapy administered, are eligible);\n10. Subjects testing positive to one of the following viruses: HIV, HBV or HCV;\n11. Any of the following conditions:\n\n * Serious or non-healing wound, ulcer, or bone fracture;\n * History of abdominal fistula, gastro-intestinal perforation, active diverticulitis, intra-abdominal abscess or gastro-intestinal tract bleeding within 6 months of dosing;\n * Any history of cerebrovascular accident (CVA) within 6 months of dosing;\n * Current use of therapeutic warfarin (Note: Low molecular weight heparin and prophylactic low-dose warfarin [INR<1.2 X ULN] are permitted);\n * History of bleeding disorder, including subjects with hemophilia, disseminated intravascular coagulation (DIC), or any other abnormality of coagulation potentially predisposing subjects to bleeding;\n * Poorly controlled depression or anxiety disorder, or recent (within the previous 6 months) suicidal ideation;\n12. Subjects with an ongoing requirement for immunosuppressive treatment, including the use of glucocorticoids or cyclosporin, or with a history of chronic use of any such medication within the last 4 weeks before dosing;\n13. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Histologically or cytologically confirmed advanced DTC (papillary, follicular, Hurthle cell);",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "advanced DTC (papillary, follicular, Hurthle cell)",
"criterion": "advanced DTC subtype",
"requirements": [
{
"requirement_type": "subtype",
"expected_value": [
"papillary",
"follicular",
"Hurthle cell"
]
}
]
}
]
},
{
"line": "2. Absence of sensitivity to therapeutic radioiodine;",
"criterions": [
{
"exact_snippets": "Absence of sensitivity to therapeutic radioiodine",
"criterion": "sensitivity to therapeutic radioiodine",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "3. Measurable disease, defined as at least one non-bony lesion that can be accurately measured in at least one dimension as confirmed with spiral CT scan",
"criterions": [
{
"exact_snippets": "Measurable disease, defined as at least one non-bony lesion",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "definition",
"expected_value": "at least one non-bony lesion"
}
]
},
{
"exact_snippets": "at least one non-bony lesion that can be accurately measured in at least one dimension",
"criterion": "non-bony lesion",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": "accurately measured in at least one dimension"
}
]
},
{
"exact_snippets": "confirmed with spiral CT scan",
"criterion": "confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": "spiral CT scan"
}
]
}
]
},
{
"line": "4. Life expectancy >3 months; ECOG performance status (PS) 0, 1, or 2; Karnofsky performance status of ≥60%;",
"criterions": [
{
"exact_snippets": "Life expectancy >3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "ECOG performance status (PS) 0, 1, or 2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"0",
"1",
"2"
]
}
]
},
{
"exact_snippets": "Karnofsky performance status of ≥60%",
"criterion": "Karnofsky performance status",
"requirements": [
{
"requirement_type": "status",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "%"
}
}
]
}
]
},
{
"line": "5. Subjects with a normal/acceptable hematological profile",
"criterions": [
{
"exact_snippets": "normal/acceptable hematological profile",
"criterion": "hematological profile",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"normal",
"acceptable"
]
}
]
}
]
},
{
"line": "6. Subjects with adequate renal function",
"criterions": [
{
"exact_snippets": "adequate renal function",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Presence of any of the following:",
"criterions": [
{
"exact_snippets": "Presence of any of the following",
"criterion": "condition presence",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Radiotherapy or chemotherapy <4 weeks prior to baseline visit; (Concurrent and/or prior therapy with octreotide will be allowed, provided tumor progression on this therapy has been demonstrated; Concurrent and/or prior therapy with biphosphonates will be allowed)",
"criterions": [
{
"exact_snippets": "Radiotherapy ... <4 weeks prior to baseline visit",
"criterion": "radiotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "chemotherapy <4 weeks prior to baseline visit",
"criterion": "chemotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "Concurrent and/or prior therapy with octreotide ... tumor progression on this therapy has been demonstrated",
"criterion": "octreotide therapy",
"requirements": [
{
"requirement_type": "tumor progression",
"expected_value": true
}
]
},
{
"exact_snippets": "Concurrent and/or prior therapy with biphosphonates will be allowed",
"criterion": "biphosphonates therapy",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
}
]
},
{
"line": "* Radiotherapy to ≥25% of bone marrow;",
"criterions": [
{
"exact_snippets": "Radiotherapy to ≥25% of bone marrow",
"criterion": "radiotherapy to bone marrow",
"requirements": [
{
"requirement_type": "extent",
"expected_value": {
"operator": ">=",
"value": 25,
"unit": "% of bone marrow"
}
}
]
}
]
},
{
"line": "2. Major surgery <4 weeks prior to baseline visit;",
"criterions": [
{
"exact_snippets": "Major surgery <4 weeks prior to baseline visit",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "3. Any other ongoing investigational agents within 4 weeks before dosing;",
"criterions": [
{
"exact_snippets": "Any other ongoing investigational agents within 4 weeks before dosing",
"criterion": "ongoing investigational agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<",
"value": 4,
"unit": "weeks"
}
]
}
}
]
}
]
},
{
"line": "4. Subjects who suffered from an acute cardiac event within the last 12 months, including myocardial infarction, cardiac arrythmia, admission for unstable angina, cardiac angioplasty, or stenting;",
"criterions": [
{
"exact_snippets": "acute cardiac event within the last 12 months",
"criterion": "acute cardiac event",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 12,
"unit": "months"
}
}
]
},
{
"exact_snippets": "myocardial infarction",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "cardiac arrythmia",
"criterion": "cardiac arrhythmia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "admission for unstable angina",
"criterion": "unstable angina",
"requirements": [
{
"requirement_type": "admission",
"expected_value": true
}
]
},
{
"exact_snippets": "cardiac angioplasty",
"criterion": "cardiac angioplasty",
"requirements": [
{
"requirement_type": "procedure",
"expected_value": true
}
]
},
{
"exact_snippets": "stenting",
"criterion": "stenting",
"requirements": [
{
"requirement_type": "procedure",
"expected_value": true
}
]
}
]
},
{
"line": "5. QTc prolongation (defined as QTc interval ≥500 msecs) or other significant ECG abnormalities (e.g. frequent ventricular ectopy, evidence of ongoing myocardial ischemia);",
"criterions": [
{
"exact_snippets": "QTc prolongation (defined as QTc interval ≥500 msecs)",
"criterion": "QTc interval",
"requirements": [
{
"requirement_type": "length",
"expected_value": {
"operator": ">=",
"value": 500,
"unit": "msecs"
}
}
]
},
{
"exact_snippets": "other significant ECG abnormalities (e.g. frequent ventricular ectopy, evidence of ongoing myocardial ischemia)",
"criterion": "ECG abnormalities",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"frequent ventricular ectopy",
"evidence of ongoing myocardial ischemia"
]
}
]
}
]
},
{
"line": "6. Subjects with active vascular disease, either myocardial or peripheral;",
"criterions": [
{
"exact_snippets": "active vascular disease",
"criterion": "vascular disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
},
{
"exact_snippets": "myocardial",
"criterion": "myocardial disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "peripheral",
"criterion": "peripheral vascular disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "8. Subjects with known active liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune) other than related to tumor metastases;",
"criterions": [
{
"exact_snippets": "known active liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune)",
"criterion": "active liver disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "cause",
"expected_value": [
"alcoholic",
"drug/toxin induced",
"genetic",
"autoimmune"
]
}
]
},
{
"exact_snippets": "other than related to tumor metastases",
"criterion": "liver disease related to tumor metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "9. Subjects with known CNS metastatic disease (Exception: Subjects with treated CNS metastases stable by radiographic examinations >6 months after definitive therapy administered, are eligible);",
"criterions": [
{
"exact_snippets": "known CNS metastatic disease",
"criterion": "CNS metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "treated CNS metastases stable by radiographic examinations >6 months after definitive therapy administered",
"criterion": "treated CNS metastases",
"requirements": [
{
"requirement_type": "stability",
"expected_value": true
},
{
"requirement_type": "time since therapy",
"expected_value": {
"operator": ">",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "10. Subjects testing positive to one of the following viruses: HIV, HBV or HCV;",
"criterions": [
{
"exact_snippets": "Subjects testing positive to one of the following viruses: HIV",
"criterion": "HIV",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Subjects testing positive to one of the following viruses: ... HBV",
"criterion": "HBV",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Subjects testing positive to one of the following viruses: ... HCV",
"criterion": "HCV",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Serious or non-healing wound, ulcer, or bone fracture;",
"criterions": [
{
"exact_snippets": "Serious or non-healing wound",
"criterion": "wound",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "serious"
},
{
"requirement_type": "healing status",
"expected_value": "non-healing"
}
]
},
{
"exact_snippets": "ulcer",
"criterion": "ulcer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "bone fracture",
"criterion": "bone fracture",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* History of abdominal fistula, gastro-intestinal perforation, active diverticulitis, intra-abdominal abscess or gastro-intestinal tract bleeding within 6 months of dosing;",
"criterions": [
{
"exact_snippets": "History of abdominal fistula",
"criterion": "abdominal fistula",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "History of ... gastro-intestinal perforation",
"criterion": "gastro-intestinal perforation",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "active diverticulitis",
"criterion": "diverticulitis",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
},
{
"exact_snippets": "intra-abdominal abscess",
"criterion": "intra-abdominal abscess",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "gastro-intestinal tract bleeding within 6 months of dosing",
"criterion": "gastro-intestinal tract bleeding",
"requirements": [
{
"requirement_type": "history",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Any history of cerebrovascular accident (CVA) within 6 months of dosing;",
"criterions": [
{
"exact_snippets": "Any history of cerebrovascular accident (CVA) within 6 months of dosing",
"criterion": "cerebrovascular accident (CVA)",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 6,
"unit": "months"
}
]
}
}
]
}
]
},
{
"line": "* Current use of therapeutic warfarin (Note: Low molecular weight heparin and prophylactic low-dose warfarin [INR<1.2 X ULN] are permitted);",
"criterions": [
{
"exact_snippets": "Current use of therapeutic warfarin",
"criterion": "therapeutic warfarin use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Low molecular weight heparin ... are permitted",
"criterion": "low molecular weight heparin use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "prophylactic low-dose warfarin [INR<1.2 X ULN] are permitted",
"criterion": "prophylactic low-dose warfarin use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "INR level",
"expected_value": {
"operator": "<",
"value": 1.2,
"unit": "X ULN"
}
}
]
}
]
},
{
"line": "* History of bleeding disorder, including subjects with hemophilia, disseminated intravascular coagulation (DIC), or any other abnormality of coagulation potentially predisposing subjects to bleeding;",
"criterions": [
{
"exact_snippets": "History of bleeding disorder",
"criterion": "bleeding disorder",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "hemophilia",
"criterion": "hemophilia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "disseminated intravascular coagulation (DIC)",
"criterion": "disseminated intravascular coagulation (DIC)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "any other abnormality of coagulation potentially predisposing subjects to bleeding",
"criterion": "abnormality of coagulation",
"requirements": [
{
"requirement_type": "potential to predispose to bleeding",
"expected_value": true
}
]
}
]
},
{
"line": "* Poorly controlled depression or anxiety disorder, or recent (within the previous 6 months) suicidal ideation;",
"criterions": [
{
"exact_snippets": "Poorly controlled depression",
"criterion": "depression",
"requirements": [
{
"requirement_type": "control",
"expected_value": "poorly controlled"
}
]
},
{
"exact_snippets": "anxiety disorder",
"criterion": "anxiety disorder",
"requirements": [
{
"requirement_type": "control",
"expected_value": "poorly controlled"
}
]
},
{
"exact_snippets": "recent (within the previous 6 months) suicidal ideation",
"criterion": "suicidal ideation",
"requirements": [
{
"requirement_type": "recency",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "12. Subjects with an ongoing requirement for immunosuppressive treatment, including the use of glucocorticoids or cyclosporin, or with a history of chronic use of any such medication within the last 4 weeks before dosing;",
"criterions": [
{
"exact_snippets": "ongoing requirement for immunosuppressive treatment",
"criterion": "immunosuppressive treatment",
"requirements": [
{
"requirement_type": "requirement",
"expected_value": "ongoing"
}
]
},
{
"exact_snippets": "use of glucocorticoids",
"criterion": "glucocorticoids",
"requirements": [
{
"requirement_type": "use",
"expected_value": true
}
]
},
{
"exact_snippets": "use of ... cyclosporin",
"criterion": "cyclosporin",
"requirements": [
{
"requirement_type": "use",
"expected_value": true
}
]
},
{
"exact_snippets": "history of chronic use of any such medication within the last 4 weeks before dosing",
"criterion": "chronic use of immunosuppressive medication",
"requirements": [
{
"requirement_type": "history",
"expected_value": "within the last 4 weeks before dosing"
}
]
}
]
},
{
"line": "13. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.",
"criterions": [
{
"exact_snippets": "Uncontrolled intercurrent illness",
"criterion": "intercurrent illness",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "ongoing or active infection",
"criterion": "infection",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"ongoing",
"active"
]
}
]
},
{
"exact_snippets": "psychiatric illness",
"criterion": "psychiatric illness",
"requirements": [
{
"requirement_type": "impact on compliance",
"expected_value": "would limit compliance with study requirements"
}
]
},
{
"exact_snippets": "social situations that would limit compliance with study requirements",
"criterion": "social situations",
"requirements": [
{
"requirement_type": "impact on compliance",
"expected_value": "would limit compliance with study requirements"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "7. Subjects with proliferative and/or vascular retinopathy;",
"criterions": [
{
"exact_snippets": "proliferative retinopathy",
"criterion": "proliferative retinopathy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "vascular retinopathy",
"criterion": "vascular retinopathy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "11. Any of the following conditions:",
"criterions": []
}
],
"failed_miscellaneous": []
}